AngioDynamics Names Eric Honroth CEO, Succeeding Jim Clemmer
ANGO sits 59% above its 52-week low of $9.39 on elevated volume (2.0× avg).
Summary
AngioDynamics appointed Eric Honroth as President and CEO, effective November 2, 2026. He succeeds Jim Clemmer, who will leave the Board and stay on as a consultant during the transition. Honroth's employment agreement includes a $735,000 base salary, 95% target bonus, $1.49M initial equity grant, $450,000 RSU buyout, $350,000 sign-on bonus, and $10,000 monthly commuting allowance; Clemmer will receive $30,000 per month as a consultant. The move follows the 10-K/A filed September 29 that disclosed Clemmer's retirement agreement terms. Leadership changes at a company in the middle of a Med Tech growth push can reset strategy and near-term expectations, making this a material event for traders.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Honroth's employment agreement includes a $735,000 base salary, 95% target bonus, $1.49M initial equity grant, $450,000 RSU buyout, $350,000 sign-on bonus, and $10,000 monthly commuting allowance; Clemmer will receive $30,000 per month as a consultant.
At the time of this announcement, ANGO was trading at $14.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $596.8M. The 52-week trading range was $9.39 to $16.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.